View ValuationCSL 将来の成長Future 基準チェック /36CSL利益と収益がそれぞれ年間28.1%と4.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に17.1% 27.6%なると予測されています。主要情報28.1%収益成長率27.58%EPS成長率Biotechs 収益成長29.7%収益成長率4.4%将来の株主資本利益率17.10%アナリストカバレッジGood最終更新日28 Apr 2026今後の成長に関する最新情報Csl Limited Revises Earnings Guidance for Financial Year 2026Oct 28+ 1 more updateCSL Limited Provides Earnings Guidance for the Year 2026Aug 19CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024Oct 17CSL Limited Provides Earnings Guidance for the Fiscal Year 2022Feb 16+ 1 more updateCSL Limited Provides Financial Guidance for Fiscal 2022Aug 20すべての更新を表示Recent updatesHigh number of new directors May 01CSL Limited Estimates Ordinary Dividend for the Six Months Period Ended December 31, 2025, Payable on April 9, 2026Feb 11CSL Limited Announces Chief Executive Officer ChangesFeb 10+ 1 more updateCSL Announces Five-Year (60-Month) Results from the Pivotal Phase 3 Hope-B StudyDec 09Csl Limited Revises Earnings Guidance for Financial Year 2026Oct 28+ 1 more updateCSL Limited, Annual General Meeting, Oct 28, 2025Sep 17Investor sentiment deteriorates as stock falls 20% Aug 25CSL Limited to Report First Half, 2026 Results on Feb 02, 2026Aug 25+ 1 more updateHigh number of new directors Aug 22CSL Limited Announces Unfranked Dividend for the Period of Six Months Ended June 30, 2025, Payable on October 03, 2025Aug 21Final dividend of US$1.62 announced Aug 21Full year 2025 earnings released: EPS: US$6.20 (vs US$5.47 in FY 2024) Aug 19CSL Limited Provides Earnings Guidance for the Year 2026Aug 19Health Canada Authorized CSL's Andembry (Garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (Hae)Aug 08CSL Limited announces U.S. Food and Drug Administration Approves Csl's Andembry®? (Garadacimab-Gxii) Treatment Targeting Factor Xiia with Once-Monthly Dosing for All Patients from the StartJun 18CSL Vifor Announces England's Nice Recommends Filspari®? (Sparsentan) as A Treatment Option for IgA NephropathyMay 23CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 VaccineFeb 15European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)Feb 14First half dividend of US$1.30 announced Feb 13First half 2025 earnings released: EPS: US$4.15 (vs US$3.94 in 1H 2024) Feb 12Joy Linton Resumes the Role of Chief Financial Officer of CSL LimitedFeb 11+ 2 more updatesCSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFeb 08CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)Dec 14MD, CEO & Executive Director recently sold AU$1.1m worth of stock Nov 07CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA NephropathyOct 17Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 StrainSep 14Upcoming dividend of US$1.45 per share Sep 02Final dividend of US$1.45 announced Aug 16Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023) Aug 13CSL Limited to Report First Half, 2025 Results on Feb 11, 2025Aug 13+ 2 more updatesNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 23Now 21% undervalued after recent price drop Apr 27CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA NephropathyApr 24Now 20% undervalued Mar 07CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory CommitteeMar 06Upcoming dividend of US$1.19 per share Mar 04First half dividend of US$1.19 announced Feb 16First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023) Feb 14CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024Feb 13+ 1 more updateCSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)Feb 12Now 22% undervalued Feb 12CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster BoosterDec 21CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024Dec 15CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BDec 12Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in AdultsNov 29Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia BOct 28CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024Oct 17CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza VaccinesOct 12+ 1 more updateCSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare ResourcesSep 20Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19Sep 06Upcoming dividend of US$1.29 per share at 1.4% yield Sep 04Independent Non-Executive Chairman recently sold AU$5.6m worth of stock Aug 26CSL Appoints Jeffrey Ball as First Chief Sustainability OfficerAug 18CSL Limited, Annual General Meeting, Oct 09, 2024Aug 15+ 2 more updatesFull year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022) Aug 15CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023Aug 04Upcoming dividend of US$1.07 per share at 1.1% yield Mar 02First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022) Feb 14CSL Limited Announces Interim Dividend, Payable on 5 April 2023Feb 14CSL Limited, Annual General Meeting, Oct 11, 2023Jan 10CSL Limited to Report First Half, 2023 Results on Feb 14, 2023Jan 09SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune DiseasesJan 06Independent Non Executive Director recently bought AU$74k worth of stock Oct 22Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock Sep 03Upcoming dividend of US$1.18 per share Aug 30Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021) Aug 18CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022Aug 17+ 1 more updateNow 20% undervalued Aug 13Now 21% undervalued after recent price drop Jun 19Upcoming dividend of US$1.04 per share Feb 28Independent Non-Executive Director recently bought AU$54k worth of stock Feb 25First half 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 18CSL Limited Provides Earnings Guidance for the Fiscal Year 2022Feb 16+ 1 more updateCSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.Feb 15CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.Dec 15Centerview Reportedly Role in Vifor SaleDec 09Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza VaccineNov 24MD, CEO & Executive Director recently sold AU$4.4m worth of stock Nov 06MD, CEO & Executive Director recently sold AU$4.8m worth of stock Sep 07High number of new directors Sep 02Upcoming dividend of US$1.18 per share Aug 26Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020) Aug 22CSL Limited Provides Financial Guidance for Fiscal 2022Aug 20Independent Non-Executive Director Shah Hussain has left the company Jun 26Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and OlderMar 19Independent Non-Executive Chairman recently bought AU$82k worth of stock Feb 27業績と収益の成長予測CHIA:CSL - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202817,0713,5413,4094,470156/30/202716,3553,2873,3224,233166/30/202615,7671,3843,0593,4231612/31/202515,4071,3962,4833,604N/A9/30/202515,4832,1992,5233,583N/A6/30/202515,5583,0022,5633,561N/A3/31/202515,3942,8752,2153,258N/A12/31/202415,2302,7481,8672,954N/A9/30/202415,0152,6951,6882,859N/A6/30/202414,8002,6421,5082,764N/A3/31/202414,4902,5571,3332,727N/A12/31/202314,1792,4721,1582,690N/A9/30/202313,7452,3331,0342,646N/A6/30/202313,3102,1949092,601N/A3/31/202312,5072,1567652,392N/A12/31/202211,7052,1186222,182N/A9/30/202211,1332,1861,0012,406N/A6/30/202210,5622,2551,3812,629N/A3/31/202210,5872,2901,2512,679N/A12/31/202110,6122,3251,1212,728N/A9/30/202110,4612,3501,5383,175N/A6/30/202110,3102,3751,9553,622N/A3/31/202110,1452,5202,1273,597N/A12/31/20209,9802,6652,2993,571N/A9/30/20209,5652,3841,7103,030N/A6/30/20209,1512,1031,1212,488N/A3/31/20209,0482,0541,0092,418N/A12/31/20198,9442,0068972,347N/A9/30/20198,7421,962N/A1,996N/A6/30/20198,5391,919N/A1,644N/A3/31/20198,4061,861N/A1,621N/A12/31/20188,2741,803N/A1,597N/A9/30/20188,0941,766N/A1,750N/A6/30/20187,9151,729N/A1,902N/A3/31/20187,6661,674N/A1,662N/A12/31/20177,4171,618N/A1,422N/A9/30/20177,1821,478N/A1,335N/A6/30/20176,9471,337N/A1,247N/A3/31/20176,8021,333N/A1,192N/A12/31/20166,6561,329N/A1,138N/A9/30/20166,3861,286N/A1,158N/A6/30/20166,1151,242N/A1,179N/A3/31/20165,9831,324N/A1,296N/A12/31/20155,8501,406N/A1,413N/A9/30/20155,6541,392N/A1,388N/A6/30/20155,4591,379N/A1,364N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CSLの予測収益成長率 (年間28.1% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: CSLの収益 ( 28.1% ) はAustralian市場 ( 12% ) よりも速いペースで成長すると予測されています。高成長収益: CSLの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: CSLの収益 ( 4.4% ) Australian市場 ( 6.4% ) よりも低い成長が予測されています。高い収益成長: CSLの収益 ( 4.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CSLの 自己資本利益率 は、3年後には低くなると予測されています ( 17.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 14:42終値2026/05/01 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CSL Limited 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Saul HadassinBarrenjoey Markets Pty LimitedThomas WakimBell PotterLyanne HarrisonBofA Global Research24 その他のアナリストを表示
CSL Limited Estimates Ordinary Dividend for the Six Months Period Ended December 31, 2025, Payable on April 9, 2026Feb 11
CSL Limited Announces Unfranked Dividend for the Period of Six Months Ended June 30, 2025, Payable on October 03, 2025Aug 21
Health Canada Authorized CSL's Andembry (Garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (Hae)Aug 08
CSL Limited announces U.S. Food and Drug Administration Approves Csl's Andembry®? (Garadacimab-Gxii) Treatment Targeting Factor Xiia with Once-Monthly Dosing for All Patients from the StartJun 18
CSL Vifor Announces England's Nice Recommends Filspari®? (Sparsentan) as A Treatment Option for IgA NephropathyMay 23
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 VaccineFeb 15
European Commission Approves CSL's ANDEMBRY®? (Garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)Feb 14
CSL Behring's Gene Therapy HEMGENIX®? (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia BFeb 08
CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA NephropathyOct 17
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 StrainSep 14
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineMay 23
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA NephropathyApr 24
CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory CommitteeMar 06
CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024Feb 13+ 1 more update
CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)Feb 12
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster BoosterDec 21
CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BDec 12
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in AdultsNov 29
Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia BOct 28
CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza VaccinesOct 12+ 1 more update
CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare ResourcesSep 20
Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19Sep 06
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune DiseasesJan 06
CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022Aug 17+ 1 more update
CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.Dec 15
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza VaccineNov 24
Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and OlderMar 19